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1  |  INTRODUC TION
Plasma fibrinogen is produced by the liver, and its expression 
may be increased along with the inflammatory burden. For this 
reason, fibrinogen is considered a positive acute- phase protein 
similar to erythrocyte sedimentation rate (ESR) and C- reactive 
protein (CRP).1,2 Meanwhile, serum albumin is also produced by 
the liver but its expression may be decreased in response to the 
inflammatory burden, unlike fibrinogen. For this reason, serum al-
bumin is categorised to a negative acute- phase protein similar to 
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could reflect the cross- sectional activity and predict poor outcomes in patients with 
antineutrophil	cytoplasmic	antibody	(ANCA)-	associated	vasculitis	(AAV).
Methods: This	 cross-	sectional	 study	 included	 54	 immunosuppressant	 drug-	naïve	
patients	with	AAV	who	had	the	results	of	plasma	fibrinogen	and	serum	albumin	at	
diagnosis. Clinical and laboratory data at diagnosis were collected, and all- cause 




13	GPA	 and	 8	 EGPA).	 FAR	was	 significantly	 correlated	with	Birmingham	 vasculitis	
activity	score	(BVAS;	r	=	0.271),	erythrocyte	sedimentation	rate	(ESR;	r	=	0.668)	and	
C- reactive protein (CRP; r	=	0.638).	High	BVAS	was	defined	as	BVAS	≥16,	and	 the	
cut-	off	 of	 FAR	 at	 diagnosis	was	 set	 as	 0.118.	 AAV	 patients	with	 FAR	 at	 diagnosis	





Conclusions: Fibrinogen to albumin ratio at diagnosis could reflect the cross- sectional 
BVAS	but	could	not	predict	poor	outcomes	in	patients	with	AAV.
K E Y W O R D S
antineutrophil cytoplasmic antibody, birmingham vasculitis activity score, fibrinogen to 
albumin ratio, vasculitis
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transferrin.1,3 Recently, a new concept of an inflammation- related 
index	using	these	two	variables,	fibrinogen	to	albumin	ratio	(FAR),	
has been introduced.4	 Theoretically,	 FAR	may	maximise	 the	 po-
tential of reflecting the inflammatory burden by placing a positive 
acute- phase protein on the molecule and a negative acute- phase 
protein	on	the	denominator.	A	previous	study	demonstrated	that	
an	inverse	form	of	FAR,	albumin	to	fibrinogen,	was	useful	for	mon-
itoring the cross- sectional activity of rheumatoid arthritis, which 
is a typical auto- inflammatory disease.5 In addition to the ability to 
reflect the current inflammatory burden, the clinical significance 
of	FAR	as	a	predictor	of	the	prognosis	of	several	cancers	has	been	
also reported.6,7
Microscopic	 polyangiitis	 (MPA),	 granulomatosis	 with	 poly-
angiitis	 (GPA)	 and	 eosinophilic	 granulomatosis	 with	 polyangiitis	
(EGPA)	belong	to	a	group	of	antineutrophil	cytoplasmic	antibody	
(ANCA)-	associated	 vasculitis	 (AAV).8 They share a common fea-
ture of small- vessel necrotising vasculitis in pathological findings; 
however, they present quite different clinical manifestations. 
MPA	frequently	induce	rapid	progressive	glomerulonephritis	and	
pulmonary	 capillaritis,	 whereas	 GPA	 primarily	 exhibits	 granulo-
matous inflammation in both upper and lower respiratory tracts 
and occasionally necrotising crescentic glomerulonephritis. Unlike 
MPA	and	GPA,	EGPA	has	additional	clinical	features	of	allergic	and	
eosinophilic components.9
Given	 that	 FAR	 is	 an	 index,	 which	 is	 composed	 of	 reciprocal	
acute- phase proteins1 and it is proved to reflect the current inflam-
matory burden,5	it	can	be	inferred	that	FAR	will	be	useful	as	an	index	
to	reflect	the	cross-	sectional	activity	in	AAV	patients.	However,	to	




2  |  PATIENTS AND METHODS
2.1  |  Patients
This	study	included	54	immunosuppressant	drug-	naïve	AAV	patients	
having the results of both plasma fibrinogen and serum albumin at 
the	 time	 of	 diagnosis.	 Based	 on	 the	 European	 Medicine	 Agency	
algorithm	 for	 AAV	 and	 polyarteritis	 nodosa	 proposed	 in	 20078 
and the revised International Chapel Hill Consensus Conference 
Nomenclature	of	Vasculitides	suggested	in	2012,9 all patients were 
initially	diagnosed	with	AAV	at	 the	Division	of	Rheumatology,	 the	
Department of Internal Medicine, Yonsei University College of 
Medicine, Severance Hospital between October 2000 and March 
2020.	All	patients	were	followed	up	for	at	least,	more	than	3	months	
from diagnosis and had no serious medical conditions such as coex-
isting malignancies and serious infections. This study was approved 
by	 the	 Institutional	 Review	Board	 (IRB)	 of	 Severance	Hospital	 (4-	
2017-	0673).	The	need	 for	patients’	written	 informed	consent	was	
waived, as this was a retrospective study.








follow- up duration was defined as the period between the time of di-
agnosis	of	AAV	and	the	last	visit	for	patients	without	poor	outcomes,	
whereas it was defined as the period between the time of diagnosis to 
the occurrence of each poor outcome.






gen (g/dl)/serum albumin (g/dl).4
2.4  |  Statistical analyses
All	statistical	analyses	were	conducted	using	SPSS	software	(version	
23	for	Windows;	IBM	Corp.,	Armonk,	NY,	USA).	Continuous	variables	
were expressed as a median (interquartile range, IQR), and categorical 
variables were expressed as number and the percentage. The correla-
tion coefficient was obtained using the Pearson correlation analysis. 
The optimal cut- off was extrapolated by plotting the receiver opera-
tor characteristic (ROC) curve and selecting the maximised sum of 
sensitivity and specificity. Standardised coefficient (β) was deter-
mined by the univariable and multivariable linear regression analyses. 
Comparison of the cumulative survivals rates between two groups 
was performed by the Kaplan- Meier survival analysis with the log- 
rank test. p- values < 0.05 were considered statistically significant.
3  |  RESULTS
3.1  |  Characteristics at diagnosis
The	median	age	was	65.5	years,	and	59.3%	of	patients	were	women.	
Of	 54	 patients,	 61.1%	 of	 patients	 had	MPA,	 24.1%	 had	 GPA	 and	
14.8%	had	EGPA.	Forty-	six	of	54	patients	had	ANCA.	The	median	
BVAS,	 ESR	 and	CRP	were	13.0,	 53.5	mm/h	 and	9.0	mg/l,	 respec-
tively.	 The	 most	 common	 comorbidity	 was	 hypertension	 (35.2%),	
followed	by	chronic	kidney	disease	(stage	3–	5;	33.3%).	The	median	
plasma	fibrinogen,	serum	albumin	and	FAR	were	0.38	g/dl,	3.7	g/dl	
and 0.10, respectively (Table 1).
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3.2  |  Correlation of variables at diagnosis
Fibrinogen	to	albumin	ratio	was	significantly	correlated	with	BVAS	
(r	=	0.271),	ESR	(r	=	0.668)	and	CRP	(r	=	0.638).	However,	it	was	not	
correlated with age (Figure 1).
3.3  |  High BVAS
Since	BVAS	is	a	continuous	variable,	we	could	not	obtain	the	optimal	
cut-	off	of	FAR	at	diagnosis	 for	 reflecting	 the	high	activity	of	AAV	
based	on	BVAS.	For	this	reason,	we	arbitrarily	defined	the	highest	
tertile	of	BVAS	as	high	BVAS	(BVAS	at	diagnosis	≥16).
3.4  |  Optimal cut- off of FAR for reflecting the 
cross- sectional high BVAS
Based	on	high	BVAS,	we	conducted	the	ROC	curve	(area	0.639,	95%	
confidence	 interval	 (CI)	0.483,	0.795)	and	could	obtain	 the	cut-	off	
of	FAR	for	reflecting	high	BVAS	at	diagnosis	at	0.118.	When	the	op-
timal	 cut-	off	 of	 FAR	 for	 the	 cross-	sectional	 high	BVAS	was	 set	 as	









3.5  |  Linear regression analysis of variables based 
on BVAS at diagnosis
In the univariable linear regression analysis, CRP (β	=	0.383)	and	FAR	
(β	 =	 0.297)	 were	 significantly	 correlated	 with	 BVAS	 at	 diagnosis.	
However, in the multivariable analysis, both CRP (β	=	0.328)	and	FAR	
(β	=	0.476)	were	not	 independently	associated	with	BVAS	at	diag-
nosis	(Table	2).	Therefore,	we	conclude	that	FAR,	in	particular	FAR	
at	 diagnosis	 ≥0.118,	 could	 reflect	 the	 cross-	sectional	 the	 activity	
of	AAV;	however,	FAR	at	diagnosis	could	not	reflect	independently	
by surpassing other variables, such as CRP, in reflecting the cross- 
sectional	BVAS.
3.6  |  Comparison of the cumulative patients’ 











































Plasma fibrinogen (g/dl) 0.382	(0.153)






cytoplasmic; CRP, C- reactive protein; ESR, erythrocyte sedimentation 
rate;	FAR,	fibrinogen	to	albumin	ratio;	GPA,	granulomatosis	with	
polyangiitis;	MPA,	microscopic	polyangiitis;	MPO,	myeloperoxidase;	P,	
perinuclear; PR3, proteinase 3.
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F I G U R E  2 Relative	risk	of	FAR	at	diagnosis	≥0.118	for	high	BVAS.	When	the	optimal	cut-	off	of	FAR	for	the	cross-	sectional	high	BVAS	was	
set	as	FAR	at	diagnosis	≥0.118,	AAV	patients	with	FAR	at	diagnosis	≥0.118	had	a	significantly	higher	risk	for	the	cross-	sectional	high	BVAS	
than	those	with	FAR	at	diagnosis	<0.118	(RR	3.361).	FAR,	fibrinogen	to	albumin	ratio;	BVAS,	Birmingham	vasculitis	activity	score,	RR,	relative	
risk. CI, confidence interval
F I G U R E  1 Correlation	between	FAR	and	variables	at	diagnosis.	FAR	at	diagnosis	was	significantly	correlated	with	BVAS,	ESR	and	CRP	but	
not	age	at	diagnosis.	FAR,	fibrinogen	to	albumin	ratio;	BVAS,	Birmingham	vasculitis	activity	score;	ESR,	erythrocyte	sedimentation	rate;	CRP,	
C- reactive protein
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coefficient (β) 95% CI p value
Standardized 
coefficient (β) 95% CI p value
Age 0.283 −0.001,	0.243 0.051
Female gender −0.099 −5.178,	2.578 0.503
ANCA	positivity 0.251 −0.720,	10.529 0.086
Chronic kidney disease 
(stage 3– 5)
0.183 −1.542,	6.769 0.212
Diabetes mellitus 0.032 −4.603,	5.703 0.831
Hypertension −0.084 −5.138,	2.869 0.571
Dyslipidaemia 1.014 −3.086,	9.356 0.316
ESR 0.177 −0.017,	0.070 0.229
CRP 0.383 0.001,	0.066 0.007 0.328 −0.003,	0.069 0.074
FAR 0.297 1.434,	61.095 0.040 0.476 −29.072.	47.081 0.636
Abbreviations:	ANCA,	antineutrophil	cytoplasmic	antibody;	BVAS,	Birmingham	vasculitis	activity	score;	CI,	confidence	interval;	CRP,	C-	reactive	
protein;	ESR,	erythrocyte	sedimentation	rate;	FAR,	fibrinogen	to	albumin	ratio;	GPA,	granulomatosis	with	polyangiitis;	MPA,	microscopic	polyangiitis.












as high as the upper tertile.
With	 regard	 to	 reflecting	 the	 cross-	sectional	 activity	 of	 AAV,	
plasma fibrinogen and serum albumin are also well known as acute- 
phase	 proteins.	 Although	 plasma	 fibrinogen	 itself	was	 not	 proved	
to	be	significantly	correlated	with	BVAS,	it	was	inversely	correlated	
with serum albumin (r	=	−0.304,	p	=	0.025).	That	is,	the	direct	cor-
relation	between	BVAS	and	plasma	fibrinogen	is	not	clear;	however,	
it can be inferred that plasma fibrinogen indirectly reflects the in-
flammatory burden through its correlation with serum albumin. 
Then,	why	a	new	index	called	FAR	was	selected	in	this	study	instead	
of using fibrinogen or albumin itself as an index to reflect the inflam-
matory burden? First, in terms of fibrinogen, comparing the correla-
tion	coefficient	between	fibrinogen	and	FAR	for	BVAS	shows	that	
FAR	has	 a	more	 statistical	 power	 than	 fibrinogen.	Therefore,	 FAR	
can be recommended and applied as a better index if only one has 
to be selected.
Next,	in	terms	of	albumin,	in	rheumatic	diseases	where	glomer-
ulonephritis (an increase in excreting albumin) or liver disease (a de-
crease in producing albumin) is not a major clinical manifestation, 
such as rheumatoid arthritis5 or ankylosing spondylitis,10 serum al-
bumin may more directly reflect the inflammatory burden. However, 
in	patients	with	AAV,	where	proteinuria	 is	one	of	the	main	clinical	
signs,11 serum albumin may not directly reflect inflammation, and 
it is difficult to interpret serum albumin on inflammation because 
of	confounding	factors.	Therefore,	for	these	reasons,	FAR	can	be	a	
better index to reflect the inflammatory burden than each plasma 
fibrinogen or serum albumin. In addition, an index, which is com-
posed	of	two	variables	that	show	significant	correlations	with	BVAS,	
may be more flexible and reliable to reflect the inflammatory burden 
than	only	either	fibrinogen	or	albumin	is	used.	Moreover,	FAR	was	
not significantly different between patients with or without renal 
involvement (p	=	0.051),	which	means	that	renal	involvement	is	not	
the	only	factor	that	can	affect	FAR	of	AAV	patients.	This	result	is	not	














these	 results,	we	concluded	that	FAR	could	effectively	 reflect	 the	
cross-	sectional	activity	of	AAV.
For	 the	 comparison	 of	 FAR	 with	 other	 inflammatory	 markers,	
we	also	examined	the	relationship	of	CRP	and	ESR	with	BVAS.	CRP	
was	significantly	correlated	with	BVAS	(r	=	0.296,	p	=	0.030),	while	
ESR	was	 independent	of	BVAS	 (p	=	0.429).	Though	CRP	 is	one	of	
the	inflammation	markers	that	can	predict	the	cross-	sectional	BVAS,	






In	 terms	 of	 all-	cause	mortality,	 the	mechanism	of	 FAR	 to	 pre-
dict the prognosis of various cancers still remains unclear; however, 
several hypotheses have been provided: (a) fibrinogen may enhance 
cancer cell proliferation, angiogenesis and haematogenous metasta-
sis12; (b) reduced serum albumin may indicate malnutrition leading 
to reduced anti- cancer immunity13; (c) both fibrinogen and serum 
albumin may reflect the link between progressive cancer entity and 
inflammatory microenvironment.7 Of the three hypotheses, by the 
concept	of	microenvironmental	inflammation,	FAR	at	diagnosis	was	
thought	to	predict	all-	cause	mortality	in	AAV	patients;	however,	the	
results of this study concluded that it could not predict all- cause 
mortality.
In	term	of	CVA	and	CVD,	the	fibrinogen	is	converted	into	fibrin	
fibre by thrombin and calcium ion, resulting in participating in the 
coagulation process.14 That is, it may be assumed that the fibrin fibre 
production might be augmented as much as fibrinogen decreased, 
which might accelerate the coagulation system, leading to an in-
crease	 in	 the	development	of	CVA	and	CVD	during	 follow-	up.15,16 
Although	FAR	at	diagnosis	showed	a	pattern	to	predict	CVA	during	
follow- up, it did not reach statistical significance (p	 =	 0.185).	 The	
results	of	this	study	concluded	that	it	could	not	predict	CVA	or	CVD	
at all.
In terms of ESRD, plasma fibrin reflected the inflammatory 
burden well, whereas serum albumin might both reflect the in-
flammation and result from the persistent proteinuria owing to 
glomerulonephritis.11	 Therefore,	 theoretically,	 since	 FAR	 contains	
serum albumin, and the initial albumin level can reflect the amount 
of	initial	proteinuria	to	some	extent,	FAR	at	diagnosis	was	expected	
to predict the occurrence of chronic kidney disease (stage 3– 5) or 
ESRD during follow- up. However, the results of this study concluded 
that it could not predict ESRD during follow- up.
The advantage of this study is that we, for the first time, iden-
tified	the	clinical	significance	of	FAR	in	AAV	patients.	In	particular,	
in	the	absence	of	BVAS,	the	results	of	this	study	are	meaningful	in	
that it was the cornerstone of an attempt not to miss the high ac-
tivity	of	AAV	through	close	observation	and	monitoring	by	select-
ing	patients	vulnerable	to	the	aggravation	of	AAV.	However,	there	
are several limitations in this study. Since this study is a single 
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centre retrospective study, the number of patients involved was 
not large enough, the confounding variables were not strictly con-
trolled	and	the	exact	cause	of	the	high	activity	of	AAV	could	not	
be fully considered. Since our institution is currently managing the 
prospective	cohort	consisting	of	about	150	AAV	patients	and	the	
Korean vasculitis study group is establishing a nation- wide pro-
spective	AAV	patient	cohort	together,	it	will	be	possible	to	achieve	
the result of overcoming these limitations in the near future. In 
conclusion,	 FAR	 at	 diagnosis	 could	 reflect	 the	 cross-	sectional	
BVAS	but	could	not	predict	poor	outcomes	in	patients	with	AAV.
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